BioRelix developed antibiotics against drug-resistant pathogens targeting a novel class of RNA structures unique to bacteria called riboswitches. Riboswitches were first identified in the Yale laboratory of BioRelix’s co-founder, Dr. Ronald Breaker. The Company was established in 2006 and raised a total of $26 million by 2012 from Elm Street Ventures and several large life science venture funds. Brian Dixon served as CEO; Rob Bettigole represented ESV as an observer on the board of directors.